LLY - Eli Lilly succeeds in Phase 3 thyroid cancer trial for Retevmo
2023-08-22 09:28:26 ET
More on Lilly
- Eli Lilly Q2: Dividends Don't Lie
- Eli Lilly: Q2 And 2023 Revised Guidance Impressive, But Key Is Wegovy Data
- Eli Lilly and Co ( LLY ) Q2 2023 Earnings Call Transcript
- Eli Lilly Remains A Buy With Strong Sales And Possible Upside With Mounjaro
- Lilly's market cap soared 36% in Q2, eclipsing J&J, Merck, Novo Nordisk
- Seeking Alpha’s Quant Rating on Eli Lilly
- Earnings data for Eli Lilly
- Dividend scorecard for Eli Lilly
For further details see:
Eli Lilly succeeds in Phase 3 thyroid cancer trial for Retevmo